期刊
CURRENT OPINION IN PULMONARY MEDICINE
卷 25, 期 3, 页码 271-280出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCP.0000000000000570
关键词
multidrug-resistant tuberculosis; mycobacteria; nontuberculous; nontuberculous mycobacteria; regimen; tuberculosis
资金
- Insmed
Purpose of review Treatment of drug-sensitive tuberculosis (TB) is effective, whereas that of multidrug-resistant and extensively drug-resistant TB as well as nontuberculous mycobacterial (NTM) disease are less so. Therapy in general requires good adherence to potentially toxic drug regimens over prolonged periods. Poor adherence is associated with resistance development and poor outcome. This review will present promising new treatments, both new drugs and regimens, for difficult mycobacterial pulmonary infections. Recent findings A number of new and repurposed drugs including bedaquiline, delamanid, pretomanid, linezolid and clofazimine, and drug regimens, such as the STREAM trial regimens, are currently progressing from basic research through clinical trials. Summary (1) The role of bedaquiline and delamanid in TB and NTM treatment is still not clearly defined. (2) New and repurposed drugs such as pretomanid, linezolid and clofazimine have the potential to advance TB and NTM treatment. Inhaled liposomal amikacin shows promise in pulmonary NTM disease. (3) Patients with multidrug-resistant TB, extensively drug-resistant TB and NTM disease should be offered the choice to participate in drug trials that may shorten or otherwise improve their experience of treatment. (4) The use of an effective regimen based on appropriate NTM-specific drug susceptibility testing should be a cornerstone of treatment for NTM as much as it is for Mycobacterium tuberculosis treatment. (5) All new drugs identified for Mycobacterium tuberculosis should also be tested for activity against NTM, though robust tools for NTM drug susceptibility testing are required.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据